PCM
XGN icon

Prelude Capital Management’s Exagen XGN Stock Holding History

Prelude Capital Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-117
Closed -$1K – 2076
2020
Q3 		$1K Sell
117
-300
-72% -$3.86K ﹤0.01% 1743
2020
Q2 		$5K Hold
417
– – ﹤0.01% 1726
2020
Q1 		$7K Buy
417
+217
+109% +$4.31K ﹤0.01% 1194
2019
Q4 		$5K Buy
+200
New +$3.56K ﹤0.01% 1783

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's XGN Position: Q4 2020 in Review

Prelude Capital Management sold out of Exagen (XGN) in Q4 2020, closing a stake of 117 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in XGN in Q4 2019 and held it in 4 quarters. The position peaked at $7K in Q1 2020. 35 funds tracked by Wall St. Rank hold XGN as of Q4 2020.

  • Prelude Capital Management reported no remaining Exagen position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 117 Exagen shares in Q4 2020, an estimated $1K.
  • Prelude Capital Management first reported a position in Exagen in Q4 2019 and held it in 4 quarters.
  • Prelude Capital Management's Exagen position peaked at $7K in Q1 2020.
  • 35 funds tracked by Wall St. Rank held Exagen as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.